Ariad Pharmaceuticals (ARIA) was downgraded to underweight from neutral at JPMorgan. $7 price target. Expect more volatility in the near term, JPMorgan said.
Kinder Morgan (KMI) - Get Report was upgraded to outperform at BMO Capital. $26 price target. Expect Trans Mountain project to be ultimately improved and for the dividend to increase by 2019, BMO said.
3M (MMM) - Get Report was upgraded to overweight from equal-weight at Barclays. $194 price target. The stock has pulled back, but the company is leveraged to an emerging markets recovery, Barclays said.
This article was written by a staff member of TheStreet.